Literature DB >> 21825302

Development of peptide-conjugated morpholino oligomers as pan-arenavirus inhibitors.

Benjamin W Neuman1, Lydia H Bederka, David A Stein, Joey P C Ting, Hong M Moulton, Michael J Buchmeier.   

Abstract

Members of the Arenaviridae family are a threat to public health and can cause meningitis and hemorrhagic fever, and yet treatment options remain limited by a lack of effective antivirals. In this study, we found that peptide-conjugated phosphorodiamidate morpholino oligomers (PPMO) complementary to viral genomic RNA were effective in reducing arenavirus replication in cell cultures and in vivo. PPMO complementary to the Junín virus genome were designed to interfere with viral RNA synthesis or translation or both. However, only PPMO designed to potentially interfere with translation were effective in reducing virus replication. PPMO complementary to sequences that are highly conserved across the arenaviruses and located at the 5' termini of both genomic segments were effective against Junín virus, Tacaribe virus, Pichinde virus, and lymphocytic choriomeningitis virus (LCMV)-infected cell cultures and suppressed viral titers in the livers of LCMV-infected mice. These results suggest that arenavirus 5' genomic termini represent promising targets for pan-arenavirus antiviral therapeutic development.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21825302      PMCID: PMC3186971          DOI: 10.1128/AAC.00650-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

Review 1.  Morpholino antisense oligomers: the case for an RNase H-independent structural type.

Authors:  J Summerton
Journal:  Biochim Biophys Acta       Date:  1999-12-10

2.  Clinical, epidemiologic, and therapeutic aspects of Lassa fever.

Authors:  J B McCormick
Journal:  Med Microbiol Immunol       Date:  1986       Impact factor: 3.402

3.  Monoclonal antibodies to lymphocytic choriomeningitis and pichinde viruses: generation, characterization, and cross-reactivity with other arenaviruses.

Authors:  M J Buchmeier; H A Lewicki; O Tomori; M B Oldstone
Journal:  Virology       Date:  1981-08       Impact factor: 3.616

4.  Nucleotide sequence conservation at the 3' termini of the virion RNA species of New World and Old World arenaviruses.

Authors:  D D Auperin; R W Compans; D H Bishop
Journal:  Virology       Date:  1982-08       Impact factor: 3.616

5.  Protein structure of lymphocytic choriomeningitis virus: identification of the virus structural and cell associated polypeptides.

Authors:  M J Buchmeier; J H Elder; M B Oldstone
Journal:  Virology       Date:  1978-08       Impact factor: 3.616

6.  A novel mechanism for the initiation of Tacaribe arenavirus genome replication.

Authors:  D Garcin; D Kolakofsky
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

7.  Nontemplated bases at the 5' ends of Tacaribe virus mRNAs.

Authors:  R Raju; L Raju; D Hacker; D Garcin; R Compans; D Kolakofsky
Journal:  Virology       Date:  1990-01       Impact factor: 3.616

8.  Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys.

Authors:  P B Jahrling; C J Peters; E L Stephen
Journal:  J Infect Dis       Date:  1984-03       Impact factor: 5.226

9.  Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides.

Authors:  Hong M Moulton; Michelle H Nelson; Susie A Hatlevig; Muralimohan T Reddy; Patrick L Iversen
Journal:  Bioconjug Chem       Date:  2004 Mar-Apr       Impact factor: 4.774

10.  Inhibition of Japanese encephalitis virus replication in cultured cells and mice by a peptide-conjugated morpholino oligomer.

Authors:  Manu Anantpadma; David A Stein; Sudhanshu Vrati
Journal:  J Antimicrob Chemother       Date:  2010-03-18       Impact factor: 5.790

View more
  11 in total

1.  Therapeutic Targeting of CD47 to Modulate Tissue Responses to Ischemia and Radiation.

Authors:  David R Soto-Pantoja; Jeff S Isenberg; David D Roberts
Journal:  J Genet Syndr Gene Ther       Date:  2011-09-26

2.  Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model.

Authors:  Marco A Goicochea; Juan C Zapata; Joseph Bryant; Harry Davis; Maria S Salvato; Igor S Lukashevich
Journal:  Vaccine       Date:  2012-01-09       Impact factor: 3.641

Review 3.  The Virus-Host Interplay in Junín Mammarenavirus Infection.

Authors:  Giovanna Lucrecia Gallo; Nora López; María Eugenia Loureiro
Journal:  Viruses       Date:  2022-05-24       Impact factor: 5.818

Review 4.  Targeting virulence mechanisms for the prevention and therapy of arenaviral hemorrhagic fever.

Authors:  Lisa McLay; Aftab Ansari; Yuying Liang; Hinh Ly
Journal:  Antiviral Res       Date:  2012-12-20       Impact factor: 5.970

Review 5.  Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds.

Authors:  Yuchen Nan; Yan-Jin Zhang
Journal:  Front Microbiol       Date:  2018-04-20       Impact factor: 5.640

Review 6.  Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors.

Authors:  Morgan E Brisse; Hinh Ly
Journal:  Front Immunol       Date:  2019-03-13       Impact factor: 7.561

Review 7.  Advanced morpholino oligomers: a novel approach to antiviral therapy.

Authors:  Travis K Warren; Amy C Shurtleff; Sina Bavari
Journal:  Antiviral Res       Date:  2012-02-14       Impact factor: 5.970

Review 8.  Arenaviruses and lethal mutagenesis. Prospects for new ribavirin-based interventions.

Authors:  Héctor Moreno; Ana Grande-Pérez; Esteban Domingo; Verónica Martín
Journal:  Viruses       Date:  2012-11-06       Impact factor: 5.048

9.  Lymphocytic choriomeningitis virus infection in FVB mouse produces hemorrhagic disease.

Authors:  Frederick J Schnell; Sarah Sundholm; Stacy Crumley; Patrick L Iversen; Dan V Mourich
Journal:  PLoS Pathog       Date:  2012-12-27       Impact factor: 6.823

Review 10.  Novel approaches and challenges to treatment of central nervous system viral infections.

Authors:  Avindra Nath; Kenneth L Tyler
Journal:  Ann Neurol       Date:  2013-09       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.